Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Cell Death Discovery|November 3, 2025
Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcomaFrancesca Antonella Aiello, Lucrezia D'Archivio, Marika Attili, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2022
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-StudiengruppeSimone Hettmer, Corinne M Linardic, Anna Kelsey, et al.
Cancers|March 13, 2024
Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)Julia Chisholm, Henry Mandeville, Madeleine Adams, et al.
Cancers|October 16, 2024
Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998Julia Chisholm, Henry Mandeville, Madeleine Adams, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumoursReda Stankunaite, Sally L George, Lewis Gallagher, et al.
JCO Precision Oncology|January 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder AnalysisSusanne A Gatz, Julia Glade-Bender, Andrew D J Pearson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2021
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International ConsortiumJack F Shern, Joanna Selfe, Elisa Izquierdo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterationsSally L George, Elisa Izquierdo, James Campbell, et al.
JCO Precision Oncology|October 20, 2022
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility StudyOlivia Ruhen, Nathalie S M Lak, Janine Stutterheim, et al.
Nature Communications|December 15, 2023
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targetingSilvia Pomella, Matteo Cassandri, Lucrezia D'Archivio, et al.
Pageof 4